Literature DB >> 2788610

Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo.

J S Economou1, W H McBride, R Essner, K Rhoades, S Golub, E C Holmes, D L Morton.   

Abstract

Purified human and murine monocytes can be activated in vitro by human recombinant IL-2 to secrete tumour necrosis factor (TNF). TNF mRNA is detected within 4 h of addition of IL-2. Signal transduction does not appear to require expression of the Tac peptide of the IL-2 receptor. IL-2 does, however, induce Tac mRNA and Tac peptide expression on peripheral blood monocytes (PBM). In addition to these in vitro studies, PBM retrieved from IL-2-treated cancer patients and mice have been shown to have a greatly increased capacity for TNF production. These studies identify a pathway for macrophage activation by IL-2 both in vitro and in vivo. They also suggest a mechanism for some of the immunoregulatory and toxic effects of IL-2 based immunotherapy regimens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788610      PMCID: PMC1385323     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Authors:  D Pennica; G E Nedwin; J S Hayflick; P H Seeburg; R Derynck; M A Palladino; W J Kohr; B B Aggarwal; D V Goeddel
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

2.  Human actin genes are single copy for alpha-skeletal and alpha-cardiac actin but multicopy for beta- and gamma-cytoskeletal genes: 3' untranslated regions are isotype specific but are conserved in evolution.

Authors:  P Ponte; P Gunning; H Blau; L Kedes
Journal:  Mol Cell Biol       Date:  1983-10       Impact factor: 4.272

3.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

4.  Molecular cloning of cDNA encoding human interleukin-2 receptor.

Authors:  T Nikaido; A Shimizu; N Ishida; H Sabe; K Teshigawara; M Maeda; T Uchiyama; J Yodoi; T Honjo
Journal:  Nature       Date:  1984 Oct 18-24       Impact factor: 49.962

5.  Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.

Authors:  G E Nedwin; L P Svedersky; T S Bringman; M A Palladino; D V Goeddel
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

6.  Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells.

Authors:  J S Pober; M P Bevilacqua; D L Mendrick; L A Lapierre; W Fiers; M A Gimbrone
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

7.  Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes.

Authors:  S Haskill; C Johnson; D Eierman; S Becker; K Warren
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

8.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.

Authors:  J J Mulé; J Yang; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

9.  Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype.

Authors:  B Beutler; V Tkacenko; I Milsark; N Krochin; A Cerami
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Tumor necrosis factor and immunopathology.

Authors:  P F Piguet; G E Grau; P Vassalli
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 2.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

3.  Murine mesothelioma induces locally-proliferating IL-10(+)TNF-α(+)CD206(-)CX3CR1(+) M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy.

Authors:  Connie Jackaman; Teong L Yeoh; Manyual L Acuil; Joanne K Gardner; Delia J Nelson
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

4.  Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model.

Authors:  M S Palermo; M F Alves Rosa; N Van Rooijen; M A Isturiz
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

5.  Production of tumor necrosis factor alpha by monocytes from patients with pulmonary tuberculosis.

Authors:  T Takashima; C Ueta; I Tsuyuguchi; S Kishimoto
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  Different roles for interleukin-4 during the course of Toxoplasma gondii infection.

Authors:  C W Roberts; D J Ferguson; H Jebbari; A Satoskar; H Bluethmann; J Alexander
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

7.  Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways.

Authors:  L G Guidotti; S Guilhot; F V Chisari
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma.

Authors:  C Bello-Fernandez; P Oblakowski; A Meager; A S Duncombe; D M Rill; A V Hoffbrand; M K Brenner
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

9.  Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity.

Authors:  J S Economou; M Hoban; J D Lee; R Essner; S Swisher; W McBride; D B Hoon; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.

Authors:  L M Weiskirch; E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.